BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.

Apoptosis is a highly regulated form of cell death that controls normal homeostasis as well as the antitumor activity of many chemotherapeutic agents. Commitment to death via the mitochondrial apoptotic pathway requires activation of the mitochondrial pore-forming proteins BAK or BAX. Activation can be effected by the activator BH3-only proteins BID or BIM, which have been considered to be functionally redundant in this role. Herein, we show that significant activation preferences exist between these proteins: BID preferentially activates BAK while BIM preferentially activates BAX. Furthermore, we find that cells lacking BAK are relatively resistant to agents that require BID activation for maximal induction of apoptosis, including topoisomerase inhibitors and TRAIL. Consequently, patients with tumors that harbor a loss of BAK1 exhibit an inferior response to topoisomerase inhibitor treatment in the clinic. Therefore, BID and BIM have nonoverlapping roles in the induction of apoptosis via BAK and BAX, affecting chemotherapy response.

[1]  A. Strasser,et al.  Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. , 1999, Science.

[2]  S. Korsmeyer,et al.  Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis , 1999, Nature.

[3]  P. Bouillet,et al.  Bim is a suppressor of Myc-induced mouse B cell leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Tait,et al.  Bid can mediate a pro-apoptotic response to etoposide and ionizing radiation without cleavage in its unstructured loop and in the absence of p53 , 2011, Oncogene.

[5]  I. Lossos,et al.  Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. , 2010, Blood.

[6]  M. Raff,et al.  Programmed Cell Death in Animal Development , 1997, Cell.

[7]  A. Friedler,et al.  Molecular Basis of the Interaction between Proapoptotic Truncated BID (tBID) Protein and Mitochondrial Carrier Homologue 2 (MTCH2) Protein , 2012, The Journal of Biological Chemistry.

[8]  Osamu Takeuchi,et al.  Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. , 2009, Molecular cell.

[9]  Y. Pommier,et al.  Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5′-Phosphorylated DNA Double-Strand Breaks by Replication Runoff , 2000, Molecular and Cellular Biology.

[10]  P. Cartron,et al.  Nonredundant Role of Bax and Bak in Bid-Mediated Apoptosis , 2003, Molecular and Cellular Biology.

[11]  B. Dörken,et al.  Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway , 2004, Oncogene.

[12]  A. Letai,et al.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. , 2007, Cancer cell.

[13]  R. Houtkooper,et al.  MTCH2/MIMP is a major facilitator of tBID recruitment to mitochondria , 2010, Nature Cell Biology.

[14]  A. Letai,et al.  Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML , 2012, Cell.

[15]  S. Fulda,et al.  Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. , 2000, Blood.

[16]  Erinna F. Lee,et al.  Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis , 2013, Cell.

[17]  S. Tait,et al.  Requirement for Aspartate-cleaved Bid in Apoptosis Signaling by DNA-damaging Anti-cancer Regimens* , 2004, Journal of Biological Chemistry.

[18]  S. Korsmeyer,et al.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. , 2002, Cancer cell.

[19]  John Calvin Reed,et al.  Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family. , 1996, Cancer research.

[20]  V. Mootha,et al.  tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. , 2000, Genes & development.

[21]  Xiaodong Wang,et al.  Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.

[22]  C. Belka,et al.  Dihydroartemisinin Induces Apoptosis by a Bak-Dependent Intrinsic Pathway , 2010, Molecular Cancer Therapeutics.

[23]  S. Korsmeyer,et al.  Bax-Deficient Mice with Lymphoid Hyperplasia and Male Germ Cell Death , 1995, Science.

[24]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[25]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[26]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[27]  L. Greene,et al.  Nerve Growth Factor (NGF) Down-regulates the Bcl-2 Homology 3 (BH3) Domain-only Protein Bim and Suppresses Its Proapoptotic Activity by Phosphorylation* , 2002, The Journal of Biological Chemistry.

[28]  A. Strasser,et al.  Bim: a novel member of the Bcl‐2 family that promotes apoptosis , 1998, The EMBO journal.

[29]  N. Hayashi,et al.  Delayed‐onset caspase‐dependent massive hepatocyte apoptosis upon fas activation in bak/bax‐deficient mice , 2011, Hepatology.

[30]  G. Evan,et al.  Specific Requirement for Bax, Not Bak, in Myc-induced Apoptosis and Tumor Suppression in Vivo* , 2006, Journal of Biological Chemistry.

[31]  C. Thompson,et al.  Bax and Bak Independently Promote Cytochrome cRelease from Mitochondria* , 2002, The Journal of Biological Chemistry.

[32]  S. Nagata,et al.  Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver , 1995, Nature Genetics.

[33]  L. Walensky,et al.  Direct activation of full-length proapoptotic BAK , 2013, Proceedings of the National Academy of Sciences.

[34]  D. Green,et al.  Mitochondria and cell death: outer membrane permeabilization and beyond , 2010, Nature Reviews Molecular Cell Biology.

[35]  S. Kawanishi,et al.  TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells. , 1999, Biochemical and biophysical research communications.

[36]  D. Green,et al.  Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD‐specific caspase activation and independently of mitochondrial transmembrane depolarization , 1998, The EMBO journal.

[37]  N. Osheroff,et al.  Etoposide, topoisomerase II and cancer. , 2005, Current medicinal chemistry. Anti-cancer agents.

[38]  D. Tyrrell,et al.  TRAIL Inhibits Tumor Growth but Is Nontoxic to Human Hepatocytes in Chimeric Mice , 2004, Cancer Research.

[39]  E. Slee,et al.  Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release , 2000, Cell Death and Differentiation.

[40]  S. Korsmeyer,et al.  The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. , 2000, Molecular cell.

[41]  N. Tjandra,et al.  BAX Activation is Initiated at a Novel Interaction Site , 2008, Nature.

[42]  S. Korsmeyer,et al.  Bax Loss Impairs Myc-Induced Apoptosis and Circumvents the Selection of p53 Mutations during Myc-Mediated Lymphomagenesis , 2001, Molecular and Cellular Biology.

[43]  S. Korsmeyer,et al.  A Role for Proapoptotic BID in the DNA-Damage Response , 2005, Cell.

[44]  J. Hsieh,et al.  Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies , 2006, Nature Cell Biology.

[45]  K. Kinzler,et al.  Role of BAX in the apoptotic response to anticancer agents. , 2000, Science.

[46]  Y. Lerenthal,et al.  Proapoptotic BID Is an ATM Effector in the DNA-Damage Response , 2005, Cell.

[47]  J. Martinou,et al.  Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K , 1995, Nature.

[48]  W. Wilson,et al.  Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. , 2012, Blood.

[49]  D. Andrews,et al.  tBid Undergoes Multiple Conformational Changes at the Membrane Required for Bax Activation* , 2013, The Journal of Biological Chemistry.

[50]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[51]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[52]  I. Lossos,et al.  Interleukin‐4 distinctively modifies responses of germinal centre‐like and activated B‐cell‐like diffuse large B‐cell lymphomas to immuno‐chemotherapy , 2009, British journal of haematology.

[53]  Matthew J. Brauer,et al.  Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak , 1995, Nature.

[54]  I. Herr,et al.  Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.

[55]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[56]  B. Kaina.  DNA damage-triggered apoptosis: critical role of DNA repair, double-strand breaks, cell proliferation and signaling. , 2003, Biochemical pharmacology.

[57]  Y. Hsu,et al.  Nonionic Detergents Induce Dimerization among Members of the Bcl-2 Family* , 1997, The Journal of Biological Chemistry.

[58]  S. Korsmeyer,et al.  Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c , 2000, Cell Death and Differentiation.